SF Opioid Crisis Not From Allergan's Market Share, Judge Told
An economics expert for Allergan testified Wednesday in a bellwether opioid bench trial that the "extremely small" market share and promotion done for the company's two branded opioids could not have...To view the full article, register now.
Already a subscriber? Click here to view full article